Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: Technical progress or cycle of regulatory capture?
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Abraham, John & Reed, Tim, 2003. "Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?," Social Science & Medicine, Elsevier, vol. 57(2), pages 195-204, July.
- Abraham, John, 1998. "Regulating the cancer-inducing potential of non-steroidal anti-inflammatory drugs: Some lessons from the 1970s and 1980s," Social Science & Medicine, Elsevier, vol. 46(1), pages 39-51, January.
- repec:cup:apsrev:v:98:y:2004:i:04:p:613-631_04 is not listed on IDEAS
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Mulinari, Shai, 2015. "Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant," Social Science & Medicine, Elsevier, vol. 138(C), pages 217-224.
More about this item
KeywordsDrug testing; Animal models; Pharmaceutical industry; International regulation; Drug safety regulation; Carcinogenic;
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:75:y:2012:i:8:p:1433-1440. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dana Niculescu). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description .